Senesco Technologies, Inc. (“Senesco” or the “Company”) (NYSE
Amex: SNT) today reported financial results for the first quarter
of fiscal year 2012 which ended on September 30, 2011.
Highlights of the first quarter and recent weeks include:
- Initiated patient dosing in its Phase
1b/2a clinical study of SNS01-T
- Finalized an agreement with Mayo Clinic
to study SNS01-T in multiple myeloma
- Selected Criterium, Inc. to manage the
operational aspects of Phase 1b/2a clinical study
- Presented at the 2011 BIO Investor
Forum Conference
- Presented at the 13th Annual Rodman
& Renshaw Healthcare Conference
“We are pleased to have dosed our first patient at Mayo Clinic
in our first human clinical study of SNS01-T” said Leslie J.
Browne, Ph.D., President and CEO of Senesco. “After a challenging
journey to move our proprietary technology from the research lab to
bedside, we now hope to see a benefit for the patient as we work to
validate SNS01-T in the clinic.”
First Quarter Fiscal 2012 Financial Results
There was no revenue for the three month periods ended September
30, 2011 and September 30, 2010.
Research and development expenses for the three month period
ended September 30, 2011 were $634,186 compared with $1,536,507 for
the three month period ended September 30, 2010, a decrease of 59%.
The lower expenditures were primarily due to a decrease in the
costs incurred in connection with our development of SNS01-T for
multiple myeloma. Specifically, during the three month period ended
September 30, 2010, the Company incurred significant costs related
to its pivotal toxicology study and other preclinical work that it
did not incur during the three month period ended September 30,
2011.
General and administrative expenses for the three month period
ended September 30, 2011 were $645,959, compared with $668,884 for
the three month period ended September 30, 2010, a decrease of 3%.
The decrease was primarily due to a decrease in stock-based
compensation, which was partially offset by an increase in
professional fees and amortization of intangibles.
The loss applicable to common shares for the three month period
ended September 30, 2011 was $1,947,829, or $0.02 per share,
compared with a loss of $3,021,882, or $0.05 per share, for the
three month period ended September 30, 2010. The decrease in the
loss applicable to common shares was primarily the result of lower
research and development expenses.
As of September 20, 2011 Senesco had cash and cash equivalents
of $2,841,974, compared to cash and cash equivalents of $3,609,954
as of June 30, 2011. The Company believes that its cash resources
are sufficient to fund the current business plan through March 31,
2012. However the Company has the ability to raise additional
capital through its ATM facility, utilize its unused line of credit
and, if necessary, delay certain costs which will provide Senesco
with enough cash to fund operations at least through June 30,
2012.
About Multiple Myeloma
Multiple myeloma is an incurable cancer of plasma cells, a type
of white blood cell derived from B-lymphocytes, normally
responsible for the production of antibodies, in which abnormal
cells accumulate in the bone marrow leading to bone lesions and
interfering with the production of normal blood cells. Senesco was
previously granted orphan drug status for SNS01-T, the Company’s
lead drug candidate for treatment of multiple myeloma.
About Senesco Technologies, Inc.
Senesco Technologies is leveraging proprietary technology that
regulates programmed cell death, or apoptosis. Accelerating
apoptosis may have applications in treating cancer, while delaying
apoptosis may have applications treating certain inflammatory and
ischemic diseases. The Company has initiated a clinical study in
multiple myeloma with its lead therapeutic candidate SNS01-T.
Senesco has already partnered with leading-edge companies engaged
in agricultural biotechnology and is entitled to earn research and
development milestones and royalties if its gene-regulating
platform technology is incorporated into its partners’
products.
Forward-Looking Statements
Certain statements included in this press release are
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Actual results could
differ materially from such statements expressed or implied herein
as a result of a variety of factors, including, but not limited to:
the ability of the Company to consummate additional financings; the
development of the Company’s gene technology; the approval of the
Company’s patent applications; the successful implementation of the
Company’s research and development programs and collaborations; the
success of the Company's license agreements; the acceptance by the
market of the Company’s products; the timing and success of the
Company’s preliminary studies, preclinical research and clinical
trials; competition and the timing of projects and trends in future
operating performance, the Company’s ability to comply with the
continued listing standards of the NYSE Amex, as well as other
factors expressed from time to time in the Company’s periodic
filings with the Securities and Exchange Commission (the "SEC"). As
a result, this press release should be read in conjunction with the
Company’s periodic filings with the SEC. The forward-looking
statements contained herein are made only as of the date of this
press release, and the Company undertakes no obligation to publicly
update such forward-looking statements to reflect subsequent events
or circumstances.
SENESCO
TECHNOLOGIES, INC. AND SUBSIDIARY
(A DEVELOPMENT
STAGE COMPANY)
CONDENSED
CONSOLIDATED BALANCE SHEETS
(unaudited)
September
30, June 30, 2011 2011
ASSETS
CURRENT ASSETS: Cash and cash equivalents $ 2,841,974 $
3,609,954 Prepaid research supplies and expenses 1,824,519
1,446,064 Total Current Assets
4,666,493 5,056,018 Equipment, furniture and fixtures, net
3,324 3,782 Intangibles, net 3,596,709 3,524,731 Deferred income
tax assets, net - - Security deposit 5,171
12,358 TOTAL ASSETS $ 8,271,697 $ 8,596,889
LIABILITIES AND
STOCKHOLDERS' EQUITY
CURRENT LIABILITIES: Accounts payable $ 949,090 $ 559,525
Accrued expenses 651,085 509,806 Line of credit 2,199,108
2,199,108 Total Current Liabilities
3,799,283 3,268,439 Warrant liabilities 439,556 711,259
Grant payable 99,728 99,728
TOTAL LIABILITIES 4,338,567 4,079,426
STOCKHOLDERS' EQUITY: Preferred stock, $0.01 par
value, authorized 5,000,000 shares Series A 10,297 shares issued
and 3,645 and 3,690 shares outstanding, respectively 37 37
(liquidation preference of $3,827,250 and $3,792,252 at September
30, 2011 and June 30, 2011, respectively) Series B 1,200 shares
issued and outstanding 12 12 (liquidation preference of $1,260,000
and $1,230,000 at September 30, 2011 and June 30, 2011,
respectively) Common stock, $0.01 par value, authorized 250,000,000
shares, issued and outstanding 79,695,624 and 77,769,677,
respectively 796,956 777,697 Capital in excess of par 65,832,389
64,488,152 Deficit accumulated during the development stage
(62,696,264 ) (60,748,435 ) Total Stockholders'
Equity 3,933,130 4,517,463 TOTAL
LIABILITIES AND STOCKHOLDERS' EQUITY $ 8,271,697 $ 8,596,889
See Notes to Condensed Consolidated
Financial Statements
SENESCO
TECHNOLOGIES, INC. AND SUBSIDIARY
(A DEVELOPMENT
STAGE COMPANY)
CONDENSED
CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited)
Cumulative Three months ended September
30, Amounts from
2011
2010
Inception
Revenue
$ - $
- $ 1,590,000
Operating expenses: General and administrative 645,959
668,884 29,536,492 Research and development
634,186 1,536,507
19,303,544 Total operating expenses
1,280,145 2,205,391
48,840,036 Loss from
operations (1,280,145 ) (2,205,391 ) (47,250,036 ) Other
non-operating income (expense) Grant income - - 244,479
Fair value – warrant liability 271,703 319,476 8,129,370
Sale of state income tax loss – net - - 586,442 Other
noncash (expense) income, net - (111,265 ) 205,390 Loss on
extinguishment of debt - - (361,877 ) Write-off of patents
abandoned - - (1,588,087 ) Amortization of debt discount and
financing costs - - (11,227,870 ) Interest expense –
convertible notes - - (2,027,930 ) Interest (expense) income
- net
(30,541 )
(18,296 ) 380,515
Net loss (1,038,983 ) (2,015,476 ) (52,909,604 )
Preferred dividends
(908,846
) (1,006,406 )
(9,786,660 ) Loss applicable to
common shares
$ (1,947,829 )
$ (3,021,882 )
$ (62,696,264 ) Basic
and diluted net loss per common share
$
(0.02 ) $ (0.05
) Basic and diluted weighted-average number of
common shares outstanding
79,289,756
56,930,150
Senesco (AMEX:SNT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Senesco (AMEX:SNT)
Historical Stock Chart
From Jul 2023 to Jul 2024